Infectious comorbidities in pregnant patients with rheumatic diseases
Rheumatology International · 2026
DOI: 10.1007/s00296-026-06325-8 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Rheumatology International, 2026. Verfasst von Kenzhekul Konysbayeva und 5 weiteren Autor:innen. Beteiligte Einrichtung: Scientific Center for Innovative Technologies and Research, Almaty, Kazakhstan. Hauptthemen laut MEDLINE: Rheumatic Diseases, Pregnancy Complications, Infectious, Pregnancy Complications. Die Arbeit nennt 88 Literaturangaben.
Abstract (Originalsprache)
Pregnancy fundamentally reshapes maternal immunity, creating a state of immune tolerance that simultaneously increases susceptibility to infections. In women with rheumatic diseases (RDs), this vulnerability is further amplified by underlying autoimmune dysregulation and immunosuppressive therapies. Infectious comorbidities in this population represent a major challenge as they may precipitate rheumatic disease flares, contribute to maternal morbidity, and adversely affect pregnancy, including miscarriage, preterm birth, fetal growth restriction, and neonatal complications. This review aims to overview current evidence on infectious comorbidities in pregnant patients with RDs, with a focus on rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, and primary Sjögren syndrome. Disease-specific infection patterns and their impact on maternal and fetal outcomes are discussed. Literature searches were performed in Medline/PubMed, Scopus, Web of Science, and Directory of Open Access Journals (DOAJ) to identify documents on infections, prevention, and outcomes in pregnant women with RDs published up to September 2026. The influence of pregnancy-related immune modulation and immunosuppressive treatments, including corticosteroids, disease-modifying antirheumatic drugs, and biologic agents, on infection risk is examined. Preventive strategies, including preconception counseling, vaccination, targeted screening, and multidisciplinary management, are also addressed. Available evidence suggests that infectious comorbidities remain underrecognized in pregnancy counseling for women with RDs. Early risk stratification, individualized adjustment of immunosuppressive therapy, and close collaboration between rheumatologists, obstetricians, and infectologists are essential to optimize maternal and fetal outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Scientific Center for Innovative Technologies and Research, Almaty, Kazakhstan.
- Department of Chemical Disciplines, Biology and Biochemistry, South Kazakhstan Medical Academy, Shymkent, Kazakhstan.
- Department of Nursing, Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan.
- Department of Emergency Medicine and Nursing, South Kazakhstan Medical Academy, Shymkent, Kazakhstan.
- Department of Physical Medicine and Rehabilitation, Medipol University Faculty of Medicine, Istanbul, Türkiye.
- Department of Pathophysiology, Ivano-Frankivsk National Medical University, Halytska Str. 2, Ivano-Frankivsk, 76018, Ukraine. yufedorchenko@ifnmu.edu.ua.
ORCID-Profile: Kenzhekul Konysbayeva, Dinara Yerlanova, Dinara Makhanbetkulova, Umida Khojakulova, Ahmet Usen
Zitieren
APA
Konysbayeva, K., Yerlanova, D., Makhanbetkulova, D., Khojakulova, U., Usen, A., & Fedorchenko, Y. (2026). Infectious comorbidities in pregnant patients with rheumatic diseases. Rheumatology International. https://doi.org/10.1007/s00296-026-06325-8
Vancouver
Konysbayeva K, Yerlanova D, Makhanbetkulova D, Khojakulova U, Usen A, Fedorchenko Y. Infectious comorbidities in pregnant patients with rheumatic diseases. Rheumatology International. 2026. doi:10.1007/s00296-026-06325-8
BibTeX
@article{Konysbayeva2026,
author = {Konysbayeva, Kenzhekul and Yerlanova, Dinara and Makhanbetkulova, Dinara and Khojakulova, Umida and Usen, Ahmet and Fedorchenko, Yuliya},
title = {Infectious comorbidities in pregnant patients with rheumatic diseases},
journal = {Rheumatology International},
year = {2026},
doi = {10.1007/s00296-026-06325-8}
}
EUVIMED